Search
for
Sort by
Research 61–90 of 1000+
- Acneiform eruptions caused by an epidermal growth factor receptor-tyrosine kinase inhibitor ZD 1839
- Cutaneous Side Effects in Non-Small Cell Lung Cancer Patients Treated with Iressa (ZD1839), an Inhibitor of Epidermal Growth Factor
- Recent advances in the epidermal growth factor receptor/ligand system biology on skin homeostasis and keratinocyte stem cell regulation
- Dermatologic adverse events associated with afatinib: an oral ErbB family blocker
- Trichomegaly of the eyelashes following treatment with cetuximab
- Drugs and Hair Loss
- Advances in the Management of Cutaneous Toxicities of Targeted Therapies
- The Cutaneous Epidermal Growth Factor Network: Can it be Translated Clinically to Stimulate Hair Growth?
- Fatal Toxic Epidermal Necrolysis Associated With Cetuximab in a Patient With Colon Cancer
- Neutralization of IL-8 Prevents the Induction of Dermatologic Adverse Events Associated with the Inhibition of Epidermal Growth Factor Receptor
- Cetuximab-Associated Elongation of the Eyelashes
- Cutaneous Drug Eruptions Associated with the Use of New Oncological Drugs
- Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
- Trichoscopic Findings of Erosive Pustular Dermatosis of the Scalp Associated with Gefitinib
- Role for the Epidermal Growth Factor Receptor in Chemotherapy-Induced Alopecia
- Chemotherapy-induced iatrogenic injury of skin: New drugs and new concepts
- Novel acquisitions on the immunoprotective roles of the EGF receptor in the skin
- Erlotinib-Induced Skin Inflammation Is IL-1 Mediated in KC-Tie2 Mice and Human Skin Organ Culture
- Dermatologic Reactions to Targeted Therapy
- Management of Dermatologic Toxicities
- Trichomegaly of the Eyelashes After Treatment with Erlotinib in Non-small Cell Lung Cancer
- Cutaneous adverse events to systemic antineoplastic therapies: a retrospective study in a public oncologic hospital
- An overview of management of drug-induced hair and nail disorders
- Dermatologic adverse events associated with chemotherapy and targeted anticancer therapy
- A novel approach to manage skin toxicity caused by therapeutic agents targeting epidermal growth factor receptor
- Cutaneous Drug Eruptions Associated with the Use of Biologies and Cutaneous Drug Eruptions Mimicking Specific Skin Diseases
- Continuous MEK inhibition by AZD6244 (ARRY-142886) results in exhaustion of the cutaneous keratinocytic stem cell pool and resembles senescence driven skin aging
- Dermatologic Adverse Events from Cancer Treatments
- Management of Toxicities of Targeted Therapies
- Cutaneous Side Effects of Chemotherapy and Radiotherapy